P110α

Kura Oncology to Report Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, July 29, 2021
Life sciences, Health sciences, Drugs, Orphan drugs, Chloroarenes, Imidazoles, Tipifarnib, Biopharmaceutical, P110α, Head and neck cancer

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2021 financial results after the close of U.S. financial markets on Thursday, August 5, 2021.

Key Points: 
  • SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2021 financial results after the close of U.S. financial markets on Thursday, August 5, 2021.
  • ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
  • Kura Oncologyis a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • In addition, Kura is pursuing the use of tipifarnib in combination with other oncology therapeutics to address larger genetic subsets, including patients who have HRAS and/or PIK3CA-dependent HNSCC.

World-Renowned Cancer Researcher, Dr. Alan Ashworth, Joins Phoenix Molecular Designs Advisory Board

Retrieved on: 
Thursday, February 4, 2021
Branches of biology, Biology, Signal transduction, P110α, Ribosomal s6 kinase, Alan Ashworth, Cancer, Breast cancer, RSK, Phosphoinositide 3-kinase, Small molecule, Protein kinase inhibitor

SAN DIEGO and VANCOUVER,BC, Feb. 4, 2021 /PRNewswire/ - Phoenix Molecular Designs (PhoenixMD), an industry leader in the development of precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, today announced the appointment of Dr. Alan Ashworth PhD, FRS to their Advisory Board as a Scientific Advisor.

Key Points: 
  • SAN DIEGO and VANCOUVER,BC, Feb. 4, 2021 /PRNewswire/ - Phoenix Molecular Designs (PhoenixMD), an industry leader in the development of precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, today announced the appointment of Dr. Alan Ashworth PhD, FRS to their Advisory Board as a Scientific Advisor.
  • His team identified RSK2 using unbiased functional screens in search of novel drug targets for specific breast cancer subtypes.
  • This research launched Phoenix Molecular Designs in 2012, the only company to have developed a first-in-class small molecule against RSK.
  • Moreover, in the same article that highlighted RSK2 as a target for TNBC, Alan also identified PIK3CA as a target for luminal breast cancer.

BridgeBio Pharma and Affiliate Venthera Announce Dosing of First Patient in Phase 1/2 Clinical Trial of BBP-681 for Venous, Lymphatic, and Venolymphatic Malformations

Retrieved on: 
Tuesday, February 2, 2021
P110α

The majority of these cutaneous vascular malformations are driven by somatic mutations in the PIK3CA and TEK genes.

Key Points: 
  • The majority of these cutaneous vascular malformations are driven by somatic mutations in the PIK3CA and TEK genes.
  • Because BBP-681 is applied directly to skin lesions, it may minimize complications seen with systemic treatments.
  • Part 2 is a 12-week treatment, randomized, placebo-controlled, double-blind, safety and exploratory efficacy study of topically administered BBP-681.
  • Moreover, Venthera operates in a very competitive and rapidly changing environment in which new risks emerge from time to time.

Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by PI3K/Akt/mTOR Cancer Therapies and Restores Insulin Sensitivity, SynDevRx's Preclinical Studies Show

Retrieved on: 
Wednesday, October 21, 2020
Clinical medicine, Medicine, Organ systems, RTT, P110α, Hyperglycemia, Breast cancer, Hyperinsulinemia, HER2/neu, Metastatic breast cancer

"Piqray is an important new therapy for patients with HR+/Her2-, metastatic breast cancer whose tumors have a mutation in the PIK3CA gene.

Key Points: 
  • "Piqray is an important new therapy for patients with HR+/Her2-, metastatic breast cancer whose tumors have a mutation in the PIK3CA gene.
  • [4] Treatment-induced hyperglycemia has been reported as a safety concern that can lead to dose interruptions and/or drug holidays.
  • In addition, the treatment-induced hyperglycemia leads to hyperinsulinemia which in pre-clinical studies has been shown to cause resistance to these drug classes."
  • SynDevRx intends to initiate a series of Phase 2 clinical studies of its drug candidate SDX-7320 to address this major, unmet medical need.

Menarini Ricerche Announces C-PRECISE-01, a New Phase Ib/II Trial of MEN1611 in Colorectal Cancer

Retrieved on: 
Thursday, July 2, 2020
Cancer, Merck, Eli Lilly and Company, Oncology, Phosphoinositide 3-kinase, Clinical medicine, Medicine, Cetuximab, P110α, Ras GTPase, Panitumumab

The new study, called C-PRECISE-01, will evaluate MEN1611 and cetuximab in patients with PIK3CA mutated, RAS and RAF wild-type metastatic colorectal cancer (mCRC), failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.

Key Points: 
  • The new study, called C-PRECISE-01, will evaluate MEN1611 and cetuximab in patients with PIK3CA mutated, RAS and RAF wild-type metastatic colorectal cancer (mCRC), failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.
  • MEN1611 is an oral PI3K inhibitor active on the p110, and isoforms, while sparing the .
  • Preclinical and clinical evidence supports the development of MEN1611 in combination with other agents in the context of solid tumors.
  • Through the work of Menarini Silicon Biosystems, Menarini is also developing advanced technologies and products to study rare cells with single-cell precision.

Menarini Ricerche Announces C-PRECISE-01, a New Phase Ib/II Trial of MEN1611 in Colorectal Cancer

Retrieved on: 
Thursday, July 2, 2020
Cancer, Merck, Eli Lilly and Company, Oncology, Phosphoinositide 3-kinase, Clinical medicine, Medicine, Cetuximab, P110α, Ras GTPase, Panitumumab

The new study, called C-PRECISE-01, will evaluate MEN1611 and cetuximab in patients with PIK3CA mutated, RAS and RAF wild-type metastatic colorectal cancer (mCRC), failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.

Key Points: 
  • The new study, called C-PRECISE-01, will evaluate MEN1611 and cetuximab in patients with PIK3CA mutated, RAS and RAF wild-type metastatic colorectal cancer (mCRC), failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.
  • MEN1611 is an oral PI3K inhibitor active on the p110, and isoforms, while sparing the .
  • Preclinical and clinical evidence supports the development of MEN1611 in combination with other agents in the context of solid tumors.
  • Through the work of Menarini Silicon Biosystems, Menarini is also developing advanced technologies and products to study rare cells with single-cell precision.

QIAGEN Launches FFPE and Liquid Biopsy PIK3CA Diagnostics in Europe to Enhance Precision Medicine in Advanced Breast Cancer

Retrieved on: 
Monday, February 3, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Natural sciences, Articles, Biology, Biotechnology, Medical software, Qiagen, Laboratory techniques, Molecular biology, P110α, Polymerase chain reaction, Phosphoinositide 3-kinase, Cancer

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the CE-marking and launch of its therascreen PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients with a PIK3CA mutation.

Key Points: 
  • QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the CE-marking and launch of its therascreen PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients with a PIK3CA mutation.
  • All QIAGEN therascreen PIK3CA tests leverage QIAGENs worldwide co-exclusive license from Johns Hopkins University for PCR-based companion diagnostics based on detection of mutations in the PIK3CA gene.
  • 1 in 8 women in Europe will develop breast cancer before the age of 85, making it the most common form of cancer in female patients.
  • We are convinced that our therascreen PIK3CA Kit, which expands our market-leading therascreen portfolio of companion diagnostics, will provide a valuable testing option for those seeking new ways to combat advanced breast cancer.

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020
Biotechnology, Pharmaceutical, Health, Enzymes, Branches of biology, Catalysts, PIK3CB, Bisphosphate, Phosphatidylinositol, Phosphoinositide 3-kinase, Cell signaling, P110α, PI4K2A

The "Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) pipeline Target constitutes close to 14 molecules.
  • The latest report Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform - Pipeline Review, H2 2019, outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit beta isoform is an enzyme encoded by the PIK3CB gene.

Large-Scale Study Shows Guardant360 Effectively Guides Precision Oncology Treatment in Metastatic Breast Cancer Patients

Retrieved on: 
Friday, December 13, 2019
Medicine, Clinical medicine, Branches of biology, RTT, Breast cancer, Oncology, Biopsy, Cancer, Precision medicine, P110α, Tumour heterogeneity

Guardant is well-positioned to guide what represents the dawn of a new era in personalized oncology for all patients with metastatic breast cancer.

Key Points: 
  • Guardant is well-positioned to guide what represents the dawn of a new era in personalized oncology for all patients with metastatic breast cancer.
  • Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics.
  • Strategies for obtaining bone biopsy specimens from breast cancer patients - Past experience and future directions.
  • Plasma sequencing demonstrates that breast cancer patients have a higher prevalence of clonal and multiple PIK3CA mutations than other solid tumor patients.

Caris Life Sciences to Present Data Evaluating PI3K Pathway Alterations at the 2019 San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Tuesday, December 10, 2019
Protein kinases, P110α, Protein kinase B, Phosphoinositide 3-kinase, Caris, Breast cancer, AKT1, Health, Medicine, Branches of biology

The full results will be featured in Poster Session 4 on Friday, December 13, from 7:00-9:00 a.m. CT at the 2019 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas (Presentation #P4-09-04).

Key Points: 
  • The full results will be featured in Poster Session 4 on Friday, December 13, from 7:00-9:00 a.m. CT at the 2019 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas (Presentation #P4-09-04).
  • The poster is titled, "Prevalence of phosphatidylinositol-3-kinase (PI3K) pathway alterations and co-alteration of other markers in breast cancer."
  • Of the 4,895 molecular profiles submitted to Caris Life Sciences, 72.7% had at least one alteration in the PIK3CA-AKT1-PTENpathway.
  • Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets.